We came across a bullish thesis on Day One Biopharmaceuticals, Inc. (DAWN) on Twitter by Pharmdca. In this article, we will summarize the bulls’ thesis on DAWN. Day One Biopharmaceuticals, Inc. (DAWN)'s share was trading at $8.60 as of March 4th.
[caption id="attachment_570723" align="aligncenter" width="750"]DAWN is an undervalued commercial-stage oncology company with a long-term target in the mid-$30s, driven by its total addressable market (TAM) and strong pipeline. Its lead drug, OJEMDA, has quickly gained traction,...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.